NCT06564896 Comparative Assessment of Sleep Positive Airway Pressure Modalities (CASPAM)
| NCT ID | NCT06564896 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National University of Malaysia |
| Condition | Obstructive Sleep Apnea |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-09-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Obstructive sleep apnea (OSA) has been one of the topmost global health problems. It is an underdiagnosed disease which have a huge burden on healthcare if left untreated. Almost 80-90% of adults are underdiagnosed of OSA Obesity primarily is one of the supreme risk factors for developing OSA. Globally, obesity cases have risen affecting almost two billion people. According to National Health and Morbidity Survey (NHMS) 2019, 1 in 2 adults in Malaysia were overweight or obese. Report from World Obesity Atlas 2023 predicts that adult obesity will rise 4.7% annually from 2020 - 2035, while child obesity will increase by 5.3% per year over similar timeline. Overweight individuals will have a significant economic impact on Malaysia's Gross Domestic Product (GDP) by 2035 by 2.8% which is estimated to be about RM 3.2 trillion. Sequalae of OSA is divided into two (cardiovascular-metabolic effect and neurocognitive effect). This group of patients are at high risk of developing hypertension, insulin resistance, dyslipidemia which then leads to pulmonary hypertension and heart failure. More importantly, from the neurocognitive point of view, persistent sleep deprivation will lead to poor concentration, impaired memory, personality changes affecting overall self-performance which can lead to depression and compromising safety as they have higher risk of work-related accidents.
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 18 years. * Patients diagnosed with moderate to severe OSA (based on AHI classification from sleep study performed). * Patients who are able to understand and answer the questionnaire given. Exclusion Criteria: * Patients who are unable to give consent to the study. * Patients who have been diagnosed with OSA and already on CPAP machine. * Patients who had underlying Obesity Hypoventilation Syndrome (OHS). * Patients who had underlying co-morbidities that worsen apnea symptoms, such as congestive cardiac failure, active malignancy, narcolepsy, active alcohol or drug abuse, treatment-refractory dementia, psychotic illness and active use of drugs that disturb the sleep architecture (i.e hypnotics or stimulants of central nervous system).
Contact & Investigator
Mohamed Faisal Abdul Hamid, MBBS(IIUM)
PRINCIPAL INVESTIGATOR
National University of Malaysia
Frequently Asked Questions
Who can join the NCT06564896 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obstructive Sleep Apnea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06564896 currently recruiting?
Yes, NCT06564896 is actively recruiting participants. Contact the research team at faisal.hamid@ppukm.ukm.edu.my for enrollment information.
Where is the NCT06564896 trial being conducted?
This trial is being conducted at Cheras, Malaysia.
Who is sponsoring the NCT06564896 clinical trial?
NCT06564896 is sponsored by National University of Malaysia. The principal investigator is Mohamed Faisal Abdul Hamid, MBBS(IIUM) at National University of Malaysia. The trial plans to enroll 50 participants.